Yahoo
NasdaqCM - Nasdaq Real Time Price USD

PolyPid Ltd. (PYPD)

5.39 -0.20 (-3.58%)
At close: October 30 at 4:00:00 PM EDT
5.45 +0.06 (+1.11%)
After hours: October 30 at 6:25:26 PM EDT
Chart Range Bar
Loading chart for PYPD
  • Previous Close 5.59
  • Open 5.54
  • Bid 5.69 x 100
  • Ask 5.65 x 100
  • Day's Range 5.39 - 5.59
  • 52 Week Range 3.50 - 5.84
  • Volume 100,724
  • Avg. Volume 118,359
  • Market Cap (intraday) 109.48M
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) --
  • EPS (TTM) -1.44
  • Earnings Date Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 11.40
  • Motley Fool Rating Bearish

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

www.polypid.com

69

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PYPD
24.19%
S&P 500 (^GSPC)
10.73%

1-Year Return

PYPD
40.36%
S&P 500 (^GSPC)
11.11%

3-Year Return

PYPD
42.59%
S&P 500 (^GSPC)
81.91%

5-Year Return

PYPD
97.47%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -7.85M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-8M
-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

8.00
11.40 Average
5.39 Current
14.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Oppenheimer
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 10

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -74.62%

  • Return on Equity (ttm)

    -243.59%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -31.5M

  • Diluted EPS (ttm)

    -1.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.56M

  • Total Debt/Equity (mrq)

    29.18%

  • Levered Free Cash Flow (ttm)

    -17.36M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: